Seres Therapeutics (NASDAQ: MCRB)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Seres Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Seres Therapeutics Company Info
Seres Therapeutics, Inc.
News & Analysis
The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.
Positive news for the company's lead therapy and improving financials helped push the stock.
The company completed its target enrollment in a pivotal clinical study.
The company reported disappointing results from a phase 2b clinical study.
A major investor boosted its stake in the microbiome therapeutics leader.
The company's new drug could be a game changer.
The potential is significant. Unfortunately, so is the hype.
A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/24/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
MCRB earnings call for the period ending September 30, 2020.
MCRB earnings call for the period ending March 31, 2020.
MCRB earnings call for the period ending December 31, 2019.
MCRB earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.